The End of the Paclitaxel Debate: Lessons Learned and What Lies Ahead
In the years following the 2018 meta-analysis that showed a link between late-mortality and paclitaxel-coated devices, the vascular community has done the work to collect data and publish studies that now refute these initial results. VIVA has led a multipronged effort to ensure the vascular community understood these issues through educational programs, advanced our knowledge through peer-reviewed publications, and raised the national conversation through work with the FDA. The FDA decision to remove the warning from paclitaxel-coated devices represents a turning point in these efforts.
On July 17, 2023, VIVA board members, field experts, and an FDA representative examined the evolution of this controversy and key takeaways for the future.
